中国实用外科杂志

中国实用外科杂志 ›› 2011, Vol. 31 ›› Issue (10): 941-943.

• 论著 • 上一篇    下一篇

分子标记物表达预测乳腺癌蒽环类新辅助化疗疗效价值研究

陈毅作1a，2，陈灿铭1a，费    菲1a，张家新1a，陆劲松1a，狄根红1a，柳光宇1a，杨文涛1b，陆洪芬1b，沈镇宙2a，邵志敏1a，吴    炅1a   

  1. 1复旦大学附属肿瘤医院  a.乳腺外科  b.病理科，上海200032；2温州医学院附属第一医院肿瘤外科，浙江温州325000
  • 出版日期:2011-10-01 发布日期:2011-09-30

  • Online:2011-10-01 Published:2011-09-30

PDF

摘要：

目的    探讨局部晚期乳腺癌病人肿瘤组织分子生物学标记物的表达及其与新辅助化疗有效率的关系。方法    采用免疫组化的方法检测2000年1月至2010年12月复旦大学附属肿瘤医院乳腺外科收治的420例乳腺癌新辅助化疗病人化疗术后标本中雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2（HER-2）/neu、p53、Cathepsin-D、p27、cyclinD1、Bax、Ki67、TOPOII、GSTπ、MDR和Bcl-2等分子标记物的表达情况，分析这些分子标记物的表达与新辅助化疗疗效之间的关系。结果    p53或cathepsin-D或GSTπ阴性的病人化疗疗效要显著优于阳性的病人，多因素回归分析提示GSTπ和p53是独立的新辅助化疗疗效预测指标。结论    GSTπ和p53可作为判定乳腺癌蒽环类新辅助化疗方案敏感性的两个独立预测指标。

关键词: 乳腺癌, 新辅助化疗, 预测因子, 免疫组织化学

Abstract:

Expression of molecular markers predict breast cancer to neoadjuvant anthracycline chemotherapy value           CHEN Yi-zuo*, CHEN Can-ming, FEI Fei, et al.  *Department of Breast Surgery, Fudan University Shanghai Cancer Center,Shanghai 200032, China
Corresponding author: WU Jiong, E-mail：wujiong1122@vip.sina.com
Abstract    Objective    To investigate the predictive value of biological markers for responsiveness to anthracyline-based regimen in neoadjuvant systemic therapy for local advanced breast caner. Methods    Postoperative paraffin-embedded tumor samples from 420 breast cancer patients admitted between January 2000 and December 2010 in Department of Breast Surgery of Fudan University Shanghai Cancer Center were examined for expression of ER, PR, Her-2/neu and other 15 markers by immunohistochemistry, to analyze the predictive value of the biological markers for response to neoadjuvant chemotherapy. Results    Negative p53, cathepsin-D and loss of GSTπwere significantly predictive for an effective response to anthracycline-based neoadjuvant chemotherapy. In multivariate logistic regression analysis, the GSTπand p53 status were found with independent predictive value. Conclusion    Loss of GSTπand p53  independently predict the response to anthracycline-based regimen. 

Key words: breast cancer, neoadjuvant chemotherapy, predictive factors, immunohistochemistry